KRAS and cancer: A nice demonstration of that advantage for detection of cancer-associated mutations has recently been provided by Bando et al. [43] who performed multiplex single tube testing for 36 mutations in KRAS, NRAS, BRAF and PIK3CA. Unfortunately, they did not provide any data on the analytical sensitivity of the assay.